The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBatm Advanced Regulatory News (BVC)

Share Price Information for Batm Advanced (BVC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.675
Bid: 18.35
Ask: 19.00
Change: -0.075 (-0.40%)
Spread: 0.65 (3.542%)
Open: 18.75
High: 0.00
Low: 0.00
Prev. Close: 18.75
BVC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

19 Feb 2018 07:00

RNS Number : 2024F
BATM Advanced Communications Ld
19 February 2018
 

LEI: 213800FLQUB9J289RU66

 

19 February 2018

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Trading Update

FY 2017 results expected to be ahead of market expectations

 

BATM Advanced Communications Limited (LSE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following update on trading for the year ended 31 December 2017 ahead of the publication of the Group's full year 2017 results on 5 March 2018.

 

The Group had a very successful second half of the year with both of its divisions gaining new customers, securing new contracts and expanding into new territories. As a result, the Group expects to report revenue for the year ended 31 December 2017 significantly ahead of market expectations at approximately $106m, representing year-on-year growth of approximately 17%. The Group also expects to report EBITDA of approximately $7.0m (2016: $2.8m). The 2017 EBITDA includes the benefit of profits on disposal of a wholly-owned building in December 2017 of approximately $5.6m (2016 EBITDA of $2.8m included the benefit of profits on disposal of another building of approximately $3.1m).

 

The increase in revenue was driven by growth in both of the Group's divisions. The Networking & Cyber division generated significantly better-than-expected sales largely due to growth in the Group's existing ICT services and solutions business as well as its success in implementing its strategy to leverage the telecom industry transition from hardware to Network Function Virtualisation ("NFV") and Software-Defined Networking ("SDN"). During the period, as previously announced, the Group established partnerships with a number of leading telecoms and semiconductor companies such as NXP and ARM, with the respective partners offering joint solutions for NFV/SDN. Revenue growth in the Bio-Medical division was driven by stronger sales in the distribution unit, mostly based on diagnostic and molecular biology products and services.

 

Further details will be provided in the Group's full year results announcement on 5 March 2018.

 

 

Enquiries:

 

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Moti Nagar, Chief Financial Officer

Shore Capital

Mark Percy, Anita Ghanekar

+44 20 7408 4050 

Luther Pendragon

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFKFDDDBKDNBD
Date   Source Headline
2nd May 20247:00 amRNSBATM selected for TB diagnostics programme
18th Apr 20247:00 amRNSBATM to deliver Edgility to new Tier 1 customer
8th Apr 20247:00 amRNSBATM awarded new Edgility contract from Cemex
3rd Apr 20247:00 amRNSAnnual Financial Report
26th Mar 20247:00 amRNSBATM receives $2.3m cyber security orders
12th Mar 20247:00 amRNSFull Year Results
29th Feb 20247:00 amRNSNotice of Results
2nd Jan 20247:00 amRNSTotal Voting Rights
30th Nov 20237:03 amRNSBlock Listing Application
27th Nov 20237:00 amRNSBlock Listing Interim Review
30th Oct 20237:00 amRNSBATM receives $3m cyber security order
23rd Oct 20237:00 amRNSADOR Diagnostics secures $7.5m investment
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20233:30 pmRNSHolding(s) in Company
16th Oct 20237:00 amRNSNew Edgility order for US Emergency Services
9th Oct 20237:00 amRNSResponse to recent developments in Israel
6th Sep 20237:00 amRNSBATM receives $3.4m cyber security contract
29th Aug 20237:00 amRNSInterim Results
13th Jul 202311:30 amRNSResult of AGM and Director Appointment
8th Jun 20237:00 amRNSNotice of Annual General Meeting
6th Jun 20237:00 amRNSCapital Markets Day
5th Jun 20237:00 amRNSNew contract win for Edgility
10th May 20232:30 pmRNSCapital Markets Day and Investor Presentation
17th Apr 20237:00 amRNSEdgility rollout progressing ahead of schedule
4th Apr 20233:30 pmRNSAnnual Financial Report
6th Mar 20237:00 amRNSFull Year Results
24th Feb 20237:00 amRNSNotice of Results
1st Feb 20237:00 amRNSAppointment of Chief Financial Officer
9th Jan 20237:00 amRNSBATM receives $26m cyber security order
3rd Jan 20233:30 pmRNSGrant of Options
21st Dec 202212:00 pmRNSResult of AGM
21st Dec 20227:00 amRNSTransaction in Own Shares and TVR
20th Dec 20227:00 amRNSTransaction in Own Shares and TVR
19th Dec 20227:00 amRNSTransaction in Own Shares and TVR
16th Dec 20227:00 amRNSTransaction in Own Shares and TVR
15th Dec 20227:00 amRNSTransaction in Own Shares and TVR
14th Dec 20227:00 amRNSTransaction in Own Shares and TVR
13th Dec 20227:00 amRNSTransaction in Own Shares and TVR
9th Dec 20227:00 amRNSTransaction in Own Shares and TVR
8th Dec 20227:00 amRNSTrading Update
25th Nov 20221:00 pmRNSBlock Listing Interim Review
24th Nov 20224:00 pmRNSNotice of Annual General Meeting
27th Oct 20227:00 amRNSADOR and BIOASTER to develop STI diagnostic tests
18th Oct 20227:00 amRNSMulti-year contract with CityFibre for Edgility
6th Oct 20227:00 amRNSDirectorate Changes
24th Aug 20227:00 amRNSInterim Results
19th Jul 20227:00 amRNSAppointment of CEO of ADOR Diagnostics
11th Jul 20227:00 amRNSBATM partners with CityFibre for Edgility
16th Jun 20224:36 pmRNSPrice Monitoring Extension
26th May 20227:00 amRNSBlock Listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.